Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

Starting from a hexapeptide boronic acid lead, 3-amino bicyclic pyrazinones as novel beta-sheet dipeptide mimetics have been designed and synthesized. Side-chain manipulation of this scaffold generated a series of potent, nonpeptidic inhibitors of HCV NS3 protease.

[1]  C. Rice,et al.  Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo , 2000, Journal of Virology.

[2]  J P Griffith,et al.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. , 1998, Structure.

[3]  Ying Li,et al.  Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form , 1998, Protein science : a publication of the Protein Society.

[4]  J Cohen,et al.  The Scientific Challenge of Hepatitis C , 1999, Science.

[5]  A. Pessi.  A personal account of the role of peptide research in drug discovery: the case of hepatitis C 1 , 2001, Journal of peptide science : an official publication of the European Peptide Society.

[6]  Pieter F. W. Stouten,et al.  A molecular mechanics/grid method for evaluation of ligand–receptor interactions , 1995, J. Comput. Chem..

[7]  Walker,et al.  Hepatitis C virus: an overview of current approaches and progress. , 1999, Drug discovery today.

[8]  J. Vacca,et al.  Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. , 1998, Journal of medicinal chemistry.

[9]  A. Kwong,et al.  Hepatitis C virus NS3/4A protease. , 1998, Antiviral research.

[10]  D. Lamarre,et al.  Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[11]  U. Koch,et al.  Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. , 2000, Biochemistry.

[12]  R. De Francesco,et al.  Inhibition of the Hepatitis C Virus NS3/4A Protease , 2000, The Journal of Biological Chemistry.

[13]  F. Wilson,et al.  Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase. , 2000, Bioorganic & medicinal chemistry letters.

[14]  D. Lamarre,et al.  Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.

[15]  R. Cortese,et al.  Product inhibition of the hepatitis C virus NS3 protease. , 1998, Biochemistry.

[16]  N. Jennings,et al.  The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3–4A Proteinase , 1999, Antiviral chemistry & chemotherapy.

[17]  C. Pedregal,et al.  General method for the synthesis of 5-arylpyrrole-2-carboxylic acids , 1993 .

[18]  H. Parge,et al.  The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. , 1998, Clinical and diagnostic virology.

[19]  C. Decicco,et al.  α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitors , 2000 .

[20]  U. Koch,et al.  Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease. , 2000, Biochemistry.

[21]  H. Parge,et al.  The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.

[22]  J. Vaquero,et al.  Stereoselective double alkylation of ethyl N-boc-pyroglutamate , 1994 .